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ABSTRACT
Background. In esophageal cancer, circumferential
resection margins (CRMs) are considered to be of relevant
prognostic value, but a reliable deﬁnition of tumor-free
CRM is still unclear. The aim of this study was to appraise
the clinical prognostic value of microscopic CRM
involvement and to determine the optimal limit of CRM.
Methods. To deﬁne the optimal tumor-free CRM we
included 98 consecutive patients who underwent extended
esophagectomy with microscopic tumor-free resection
margins (R0) between 1997 and 2006. CRMs were mea-
sured in tenths of millimeters with inked lateral margins.
Outcome of patients with CRM involvement was compared
with a statistically comparable control group of 21 patients
with microscopic positive resection margins (R1).
Results. A cutoff point of CRM at B1.0 mm and[1.0 mm
appeared to be an adequate marker for survival and prog-
nosis (both P\0.001). The outcome in patients with
CRMs B1.0 and[0 mm was equal to that in patients with
CRM of 0 mm (P = 0.43). CRM involvement was an
independent prognostic factor for both recurrent disease
(P = 0.001) and survival (P\0.001). Survival of patients
with positive CRMs (B1 mm) did not signiﬁcantly differ
from patients with an R1 resection (P = 0.12).
Conclusion. Involvement of the circumferential resection
margins is an independent prognostic factor for recurrent
disease and survival in esophageal cancer. The optimal
limit for a positive CRM is B1 mm and for a free CRM is
[1.0 mm. Patients with unfavorable CRM should be
approached as patients with R1 resection with corre-
sponding outcome.
The rising incidence and poor prognosis of esophageal
adenocarcinoma have intensiﬁed research efforts to ﬁnd
better staging modalities, early detection, and treatment
methods.
1,2 Surgery, as the only curative option, provides
better outcome with local tumor control than nonsurgical
treatment.
3,4 Histological examination of surgical resection
margins is a standard procedure to determine the radicality
(denominated as R) of resection. It is crucial that resection
margins are microscopically free of tumor (R0) to prevent
local recurrences and avoid consequently poor survival.
5,6
In rectal cancer, involvement of circumferential resec-
tion margins (CRMs) is regarded as a highly signiﬁcant
predictor of local recurrence, prognosis, and survival.
7–10
This led to an alteration of practice, with recommendations
for preoperative (chemo)radiotherapy with complete
resection of the whole mesorectum in order to reduce the
rate of CRM involvement.
11
The role of CRMs in predicting local recurrence in
esophageal carcinoma was ﬁrst described by Sagar et al.
12
Subsequently, the role of CRMs in esophageal cancer has
been investigated during the past decade. In contrast with
the stomach, small bowel, and colon, the esophagus lacks a
serosal layer. Hence, tumor expansion encounters only a
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involvement of CRMs depends upon a combination of
tumor location and extension (ingrowth), variable esopha-
geal wall thickness, and surgical technique. Therefore,
CRMs could serve as a requirement for better local treat-
ment and, similar to in colorectal surgery, as a useful
quality indicator of surgery.
7,9 Besides the presence of
nodal metastases, lymph vascular space involvement, and
intramural metastases, CRM involvement predicts poor
prognosis.
13 Some studies showed that microscopic tumor
within 1 mm of the inked circumferential margin, which
would be regarded as a potentially curative resection (R0),
doubles the risk of mortality in the short to medium term
(3-year survival).
12,14 However, there is a lack of conclu-
sive clinical data for a ﬁxed deﬁnition of the optimal limit
of tumor-free CRMs in esophageal cancer. Many centers
still do not take into account CRMs as a routinely per-
formed item. Furthermore, the literature about the clinical
value of CRMs in esophageal cancer is sparse. Especially
with current advanced staging procedures and selective use
of neoadjuvant treatment, the clinical relevance of CRMs
should be further examined.
Aim of this study was to appraise the clinical prognostic
value of microscopic circumferential margin involvement
in esophageal cancer and that of other histopathologic
measurements inﬂuencing CRMs. CRM measurements
were performed and we assessed whether it could be a
relevant clinical prognostic factor regarding local recur-
rence and survival. Moreover, we determined the exact
optimal limit of CRMs (in tenths of millimeters). Clinical
recommendations and optimal treatment policy are also
discussed.
PATIENTS AND METHODS
Study Design
This study was performed in 98 patients with cancer of
the esophagus or gastroesophageal junction who underwent
curative intended surgery from 1997 to 2006 in our tertiary
referral university hospital. All patients underwent radical
esophageal resection performed by the same surgical
group, consisting of two experienced surgeons. For eval-
uation of the circumferential resection margins (CRMs)
patients had a microscopic free surgical resection margin,
an R0 resection, without evidence of distant metastases.
Patients with microscopically positive resection margins,
an R1 resection (deﬁned as cases with presence of micro-
scopic tumor cells within 1 mm of the proximal or distal
surgical resection margins), were used as a control group
for survival analysis. The patients in the latter group were
treated by the same surgical group during the period 1992–
2006 (n = 21 patients). This group was statistically com-
parable to the study group (R0) regarding preoperative
management, surgical procedures, and patient and tumor
characteristics.
Preoperative Management
Staging was performed according to the 6th Interna-
tional Union against Cancer (UICC) tumor–node–
metastasis classiﬁcation, which was preoperatively deter-
mined by conventional staging modalities, including
endoscopic ultrasonography (EUS) in combination with
ﬁne-needle aspiration (FNA) and computed tomography
(CT) of the neck, chest, and abdomen, with ultrasonogra-
phy of the cervical region on indication.
15 All patients with
a T3–4 and/or N1 tumor were additionally staged by
ﬂuorodeoxyglucose positron emission tomography (FDG-
PET). PET/CT images were fused when indistinctness in
staging occurred.
Inclusion and Exclusion Criteria
All included patients had a locally resectable, histolog-
ically proven cancer of the esophagus, without evidence of
distant metastases (T1-4N0-1M0-1a). Patients with distant
metastases (M1b) were excluded. The few cases with
postoperative mortality (within 30 days or in-hospital
mortality) were excluded. Patients who received neoadju-
vant treatment, all within a randomized trial, were also
excluded due to possible interfering factors.
Surgical Procedure
As a standard, we performed radical transthoracic sub-
total esophageal resection through a left thoracolaparotomy
with intrathoracic anastomoses in tumors of the distal
esophagus and gastroesophageal junction or through a right
thoracolaparotomy with a cervical anastomosis. Both were
combined with a two-ﬁeld lymphadenectomy of mediasti-
nal and abdominal lymph nodes, including the nodes at the
celiac trunk and along the upper border of the pancreas.
Histological Examination
All resected esophageal specimens were examined
macroscopically for extension of the primary tumor and
palpable lymph nodes while keeping the specimen intact.
Subsequently, the outside of the specimen was painted with
Indian ink according to the method of Quirke, for better
microscopic assessment of the surgical and lateral mar-
gins.
14 The specimens were then ﬁxed in formalin for a
minimum of 24 h before further evaluation.
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ofthespecimenwerepreparedtodeterminemacroscopically
the minimal distance between the tumor and the nearest
inked margin (Fig. 1a, b). For CRM determination, a mini-
mum of two sections were taken of this area with minimal
circumferential distance and stained with hematoxylin and
eosin (H&E) for microscopic examination (Fig. 2). The
distance from the most lateral malignant cells to the nearest
inked lateral margin (deﬁned as the CRM) was measured
microscopically in tenths of millimeters (Figs. 2 and 3).
Furthermore, all specimens were assessed for surgical
resection margins (R classiﬁcation), lymph node (LN)
involvement, and the following tumor characteristics: type
and grade of tumor, pattern of growth (pushing or satellite
growth), and types of invasion, plus lymph vascular space
involvement (LVSI = lymphogenic and/or angiogenic
growth) and perineural invasion.
Follow-Up
Relevant follow-up was obtained from the prospectively
collected data. Patients were followed every 3 months for
the ﬁrst postoperative year, every 6 months for the next
year, and then annually for 10 years. Any recurrent disease
occurring within 3 months after operation was deﬁned as
persisting disease. All patients were followed, with a
minimum of 2 years after surgery or until death. No
patients were lost to follow-up. Survival was measured in
months; cancer-related death was scored as an event; death
of any other cause was scored as end of follow-up.
Recurrence was deﬁned as tumor regrowth, determined by
FIG. 1 a Cross-sections of a specimen through the tumor with 0.5-
cm-wide slices. b Cross-section with macroscopically minimal
distance between the tumor and the nearest inked margin
FIG. 2 Microscopic example of CRM measurement, from most
lateral tumor cells to the inked outer margins; an enlargement of the
margin is shown in the inset
FIG. 3 Schematic representation of four possible microscopic
circumferential resection margins (CRM) measurements in different
esophageal cross-sections: a tumor with free CRM, measurement
performed in tenths of millimeters; b small tumor with narrow free
CRM, damage to the esophageal wall caused by surgical manipula-
tion; c large tumor, directly growing into the CRM; d tumor with
satellite (spray) growth into the CRM with few malignant cells
814 B. B. Pultrum et al.any cytologic or histologic proof, unequivocal radiologic
suspicion (CT, MRI, PET, bone scan, and ultrasonogra-
phy), and/or obvious clinical manifestations. Survival of
patients with determined tumor-free CRMs (CRM-) and
tumor-positive CRMs (CRM?) were compared with sur-
vival of the patients in the control group (R1).
A division was made in number of positive lymph nodes
(histology-proven positive lymph nodes) at [4, and in
lymph node ratio (positive lymph nodes count/examined
lymph nodes count) at [0.20; recently it appeared that
these factors are important independent prognostic indica-
tors.
16,17 Length of tumor was derived from EUS
measurement. On the grounds of previously published data,
length was divided into two groups: B5 cm and[5 cm.
18
Patient and Tumor Characteristics
The study population consisted of 98 consecutive
patients: 76 males (77.6%) and 22 females (22.4%). Mean
age was 64 years with a range of 41–81 years (Table 1).
The overall R0 percentage of all surgically treated patients
in our center was 89%. Consequently, 11% of the resec-
tions were assessed as R1 resection.
Most tumors were adenocarcinomas (n = 75, 76.5%) of
the gastroesophageal junction (n = 44, 44.9%) or distal
esophagus (n = 43, 43.9%) and classiﬁed as pT3 (n = 58,
59.2%). Lymph node metastases were found in 51 patients
(52%). Therefore, most tumors were classiﬁed as stage II
(n = 44, 44.9%) or III (n = 37, 37.8%) according to the
UICC classiﬁcation. The median number of examined
lymph nodes was 11(1–33) with a median of 1 (0–32)
tumor-positive lymph node(s). Further characteristics are
presented in Table 2.
Statistical Analyses
Data are reported as frequencies, means, and/or median
with percentages. Continuous variables were compared by
using the T-test, and the chi-square test was used for
comparison of categorical variables. Survival and recur-
rence rates were calculated by the Kaplan–Meier method
and compared using the log-rank test. Prognostic factors
for survival and recurrence were calculated by using uni-
variate and multivariate Cox regression analyses.
Multivariate Cox regression was performed by incorpo-
rating as covariates those factors that had P-value B0.1 on
univariate Cox regression analysis.
In total, 50 classiﬁcations were generated from 0.0 to
5.0 mm in steps of 0.1 mm per class. The optimal limit for
the CRMs (in tenths of millimeters) regarding outcome
(survival and local recurrence) was calculated for each
generated classiﬁcation with a receiver operating charac-
teristic (ROC) curve, with area under the curve (AUC)
analysis and Kaplan–Meier and Cox regression analysis for
survival and recurrence rate.
Univariate and multivariate logistic and linear regres-
sion analysis were used for calculating variables
inﬂuencing CRM extension, with CRM as a continuous
variable in millimeters. A P-value of\0.05 was considered
to be signiﬁcant. Statistical analysis was performed by
using the statistical package SPSS version 16.0 (SPSS Inc.,
Chicago, IL).
RESULTS
Measurement of Circumferential Resection Margins
The measured CRMs ranged from 0.0 mm to
[10.0 mm. Twenty-ﬁve patients (25.5%) had tumor cells
to the outer margins (CRM of 0.0 mm). Most of these
patients (n = 24, 96%) had advanced pT status (pT3/4)
TABLE 1 Patient and tumor characteristics
Characteristic N (%)
Gender
Male 76 (77.6)
Female 22 (22.4)
Age (years)
Median (range) 65.1 (41.4–81.8)
Localization
High/mid 11 (11.2)
Distal 43 (43.9)
GEJ 44 (44.9)
Type of resection
Left transthoracic 40 (40.8)
Right transthoracic 58 (59.2)
Site of anastomosis
Cervical 54 (55.1)
Intrathoracic 44 (44.9)
Histology
Adenocarcinoma 75 (76.5)
Squamous cell carcinoma 22 (22.4)
Adeno/squamous cell carcinoma 1 (1.0)
Tumor grade
G1 9 (9.2)
G2 44 (44.9)
G3 45 (45.9)
Tumor stage
I 15 (15.3)
IIa 31 (31.6)
IIb 13 (13.3)
III 37 (37.8)
IV 2 (2.0)
GEJ gastroesophageal junction
Circumferential Margins in Esophageal Cancer 815(P = 0.029) or had lymph node metastases (n = 18, 72%;
P = 0.021). Staging was therefore unfavorable in patients
with CRM of 0 mm (P = 0.001).
Outcome in the Study Group: Recurrent Disease
and Survival
Mean follow-up time was 37 months with a range of
4.7–124 months. In the follow-up period 44 patients
(44.9%) died due to oncological reasons.
Locoregional recurrence of disease occurred in 46% of
patients within a median period of 15.3 (3.7–78.7) months.
Year of surgery (P = 0.2), type of surgery (P = 0.83), and
type of histology (adeno/squamous) (P = 0.544) were not
associated with development of local recurrence. Recurrent
disease occurredmoreanddeveloped earlierinpatients with
CRMof0 mm(P\0.001),inpatientswithhigherpTstatus
(P\0.001), and in patients with lymph node metastasis
(P\0.001). Prognostic factors for recurrent disease on
univariate analysis are listed in Table 3. Independent prog-
nostic factors for development of local recurrence as
calculated by multivariate analysis were CRM of 0 mm
(P = 0.024) and pN1 status (P = 0.021). Although signif-
icant on univariate analysis (P = 0.031), pT status was not
signiﬁcant (P = 0.29) on multivariate analysis.
Overall 5-year survival was 47%. Year of surgery
(P = 0.611), type of surgery (P = 0.847), and type of
histology (adeno or squamous) (P = 0.879) were not
related to survival. Patients with CRM of 0 mm had sig-
niﬁcantly worse 5-year survival (24% versus 57%,
P = 0.001). Several other prognostic factors for survival
are listed in Table 3. Independent prognostic factors for
survival were presence of recurrent disease (P\0.001),
pN1 status (P = 0.025), and CRM of 0 mm (P = 0.05).
Cutoff Point of CRMs
The receiver operating characteristic (ROC) curves for
survival and recurrent disease showed the B1.0 mm and
[1.0 mm classiﬁcation to be optimal among all ROC
curves for the 50 subclassiﬁcations in tenths of millimeters.
Furthermore, survival in patients with CRM B1.0 mm and
[0 mm did not differ signiﬁcantly from survival in
patients with CRM of 0 mm (P = 0.43). Both had signif-
icantly worse outcome than those with CRM [1.0 mm
(P\0.001 and P = 0.004, respectively) (Fig. 4). Further
comparison of this cutoff point showed that survival was
worst in the CRM B1.0 mm group versus CRM[1.0 mm
(P\0.001) independent of all other classiﬁcations.
Local recurrence occurred more frequently in patients
with CRM B1.0 mm, with 32 versus 13 patients
(P = 0.001). Also, time to development of local recurrence
was signiﬁcantly shorter in patients with CRM B1.0 mm
(P = 0.002).
With the cutoff point determined as CRM B1.0 mm
(CRM?; 47 patients) with an optimal CRM limit of
[1.0 mm (CRM-; 51 patients), the rate of CRM
involvement was 48%.
Division in CRM? and CRM-
Localization of tumor (P = 0.22), type of histology
(P = 0.77), type of resection (P = 0.78), location of
anastomosis (P = 0.443), and year of surgery (P = 0.13)
were not signiﬁcantly different in the CRM [1.0 mm
(CRM-) and CRM B1.0 mm (CRM?) groups. Tumor
characteristics as growth pattern (spray or pushing) and
grade were comparable in the two groups (P = 0.077 and
P = 0.309). Lymph vascular space involvement occurred
more frequently in the CRM? group, being 54% (n = 28)
versus 23% (n = 11), respectively (P = 0.002). Perineural
invasion was equally divided (P = 0.358), as was length of
tumor[5 cm in the lumen of the esophagus (P = 0.525).
Regarding pT status, the CRM? group had a higher
number of pT3 tumors (n = 43; 84%) than did the CRM-
TABLE 2 Study measurements
Study characteristics N (%)
Circumferential margins
Free of tumor 73 (74.5)
Tumor ingrowth (0 mm) 25 (25.5)
Circumferential margins (mm)
Median 1.0
Mean 2.0
Range 0.0–10.0
Tumor growth
Spray 59 (60.2)
Pushing 39 (39.8)
Invasive growth
Lymph vascular space 39 (39.8))
Perineural 25 (25.5)
Tumor length (endoscopy), cm
B5 70 (71.4)
[5 28 (28.6)
Median (range) 4.5 (0–14)
Median nodal yield (range)
Examined number 11 (1–33)
Positive (malignant) number 1 (0–32)
Positive lymph nodes
B4 81 (82.7)
[4 17 (17.3)
Lymph node ratio
B0.20 69 (70.4)
[0.20 29 (29.6)
816 B. B. Pultrum et al.group (n = 15; 32%: P = 0.005). Also, the rate of pN1
status was higher in the CRM? group, being 63% (n = 32)
versus 36% (n = 17), respectively (P = 0.015), both
leading to a signiﬁcant higher number of stage III tumors in
the CRM? group. However, compared with pT status
(P = 0.09) and pN status (P\0.001), CRM classiﬁcation
(B1.0 mm and [1.0 mm) was an independent prognostic
factor for survival (P = 0.011). Also, for the development
of local recurrence, pN status (P\0.001) and CRM
classiﬁcation (P = 0.042) were independent prognostic
factors. This CRM classiﬁcation is therefore a stronger
prognostic factor for both survival and development of
recurrent disease than is pT status.
Prognostic Factors for More Extensive CRM
Involvement
Several factors had an impact on the extension of cir-
cumferential margins in millimeters, including tumor stage,
TABLE 3 Prognostic factors
for survival and local recurrence
of disease: univariate Cox
regression analysis
Factor Hazard ratio 95% Conﬁdential interval P value
Lower Upper
Survival
Tumor grade 1.001 0.654 1.532 0.997
Type of growth 0.824 0.446 1.525 0.539
Perineural invasion 1.636 0.847 3.160 0.143
Lymph vascular space involvement 1.984 1.082 3.639 0.027
Stage
pT stage 1.338 1.048 1.707 0.019
pN stage 5.344 2.548 11.209 \0.001
pM1a stage 3.951 1.202 12.986 0.024
CRM in mm 0.762 0.630 0.921 0.005
CRM ingrowth (0 mm) 0.357 0.193 0.659 0.001
Recurrent disease 9.768 4.427 21.631 \0.001
[4 positive lymph nodes 4.904 2.520 9.564 \0.001
Lymph node ratio[0.20 3.987 2.164 7.346 \0.001
Tumor length (cm) 1.120 1.006 1.248 0.039
Local recurrence
Tumor grade 0.967 0.632 1.479 0.876
Type of growth 0.812 0.441 1.496 0.504
Perineural invasion 2.620 1.429 4.802 0.002
Lymph vascular space involvement 2.412 1.327 4.383 0.004
Stage
pT stage 1.304 1.025 1.660 0.031
pN stage 5.357 2.634 10.859 \0.001
pM1a stage 2.709 0.646 11.367 0.173
CRM in mm 0.754 0.623 0.913 0.004
CRM ingrowth (0 mm) 0.358 0.198 0.648 0.001
[4 positive lymph nodes 6.276 3.299 11.937 \0.001
Lymph node ratio[0.20 5.237 2.883 9.514 \0.001
Tumor length (cm) 1.157 1.044 1.282 0.005
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FIG. 4 Cancer-speciﬁc survival by CRM in three categories: CRMs
with tumor ingrowth (0 mm) had similar outcome to CRMs B1m m
and [0m m ( P = 0.43); both had signiﬁcantly worse outcome
compared with CRM [1m m ( P\0.001 and P = 0.004,
respectively)
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occurrence of lymph node metastasis. These prognostic
factors inﬂuencing the extent of CRM involvement are
listed in Table 4. Independent prognostic factors for CRM
involvement were satellite growth of the tumor
(P = 0.036), pT stage (P = 0.019), and tumor size[5c m
(P = 0.01).
Resection Margins Versus CRMs
CRM- patients had signiﬁcant longer survival and
fewer events than CRM? patients and patients in the
control group with an R1 resection (P = 0.002 and
P\0.001, respectively). There was no statistically dif-
ference in survival between CRM? patients and patients of
the control group (P = 0.12) (Fig. 5).
There were signiﬁcantly more cancer-related deaths
during follow-up in the CRM? and R1 groups than in the
CRM- group, being 66.6% (n = 34) and 90% (n = 19),
respectively, versus 21% (n = 10) (P\0.001).
DISCUSSION
In the assessment of surgical radicality in esophageal
cancer, circumferential resection margin (CRM) is an inde-
pendent prognostic factor for both local recurrence and
survival. The clinical importance of CRM in current histo-
pathologic staging procedure is considerably underes-
timated. Patients with CRM involvement have worse out-
come, independent of other factors. We determined that the
best cutoff point for CRM was B1.0 mm and[1.0 mm. A
tumor-freeCRMlimit[1.0 mmseemsoptimalregardingits
prognostic value for development of recurrent disease and
survival. The rate of CRM involvement (B1.0 mm) in this
study was 48%, which is comparable to ﬁgures from other
studies.
14 Patients with CRM B1.0 mm had equal survival
compared with patients with an R1 resection.
Total lymph node count and lymph node ratio in this
study are in line with the results of other large, single-center
studies.
19,20 Although lymph node involvement occurred
more frequently in patients with CRM B1.0 mm, it had no
inﬂuence on the independent prognostic factor of CRM.
TABLE 4 Prognostic factors
for extension of circumferential
resection margins involvement,
with CRM as continuous
variable in mm: logistic and
linear regression univariate
analysis
Factor Regression coefﬁcient 95% Conﬁdential interval P value
Lower Upper
Year of surgery 0.042 -0.167 0.251 0.693
Type of resection -0.008 -0.054 0.038 0.737
Histology type -0.027 -0.099 0.045 0.465
Localization -0.015 -0.083 0.054 0.666
Tumor grade -0.031 -0.085 0.022 0.251
Stage -0.272 -0.358 -0.186 \0.001
pT stage -0.110 -0.186 -0.034 0.005
pN stage -0.073 -0.112 -0.033 \0.001
pM stage -0.010 -0.024 0.005 0.187
Tumor growth (spray) 0.052 0.012 0.092 0.011
Perineural invasion -0.036 -0.072 0.000 0.048
Lymph vascular space involvement -0.078 -0.116 -0.040 \0.001
[4 positive lymph nodes -0.040 -0.071 -0.010 0.010
Lymph node ratio[0.20 -0.047 -0.084 -0.010 0.014
Tumor length (cm) -0.370 -0.579 0.160 0.001
100
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FIG. 5 Equal cancer-speciﬁc survival of positive CRMs and R1
resections. Kaplan–Meier survival curve of patients with positive
resection margins (R1) of the control group (n = 21) and patients of
the study group with positive CRM B1 mm (CRM?)( n = 51, 52%)
and free CRM [1 mm (CRM-)( n = 47, 48%). There was no
signiﬁcant difference in survival between CRM? and R1 (P = 0.12);
signiﬁcant differences were found between CRM- with CRM? and
R1 (both P\0.001)
818 B. B. Pultrum et al.CRM classiﬁcation into B1.0 mm and [1.0 mm is also a
stronger prognostic factor for survival and local recurrence
than is pT status of the tumor.
We reappraised the prognostic value of several histo-
pathologic measurements and can afﬁrm the prognostic
importance of lymph vascular space involvement and
perineural invasion for survival and local recur-
rence.
16–18,20–22 The used classiﬁcations of [4 positive
lymph nodes and lymph node ratio [0.20 were highly
signiﬁcant for survival and recurrent disease and also
correlated with extensive CRM involvement on univariate
analysis. Our data support published reports on their use-
fulness in the estimation of prognosis for survival and add
their prognostic value for CRM involvement.
16,23
Independent factors for extensive CRM involvement
were satellite (spray-type) growth of tumor, depth of tumor
ingrowth according to pT classiﬁcation, and length of
tumor.
Other studies deﬁned CRM involvement in esophageal
cancer as presence of tumor within 1 mm of inked margins,
while no explanation is given for this choice of cutoff
point. We assume that this choice is based on the R clas-
siﬁcation of 1 mm and/or the cutoff point for CRMs in
rectal cancer of B1.0 mm. In this study we found that
margins B1.0 mm and [0 mm and margins with obvious
tumor ingrowth (0 mm) did not have different survival and
had the same prognostic value for dismal prognosis. The
receiver operating characteristic (ROC) curve and survival
analysis demonstrated the best sensitivity and speciﬁcity
for the B1.0 mm and [1.0 mm classiﬁcation out of 50
subclassiﬁcations in tenths of millimeters. Therefore, the
optimal limit of CRM involvement and its predictive value
for outcome should be[1.0 mm.
As in rectal cancer, patients with esophageal carcinoma
and CRM involvement are more likely to develop local
recurrence, while local recurrence of disease is the stron-
gest predictor for dismal outcome.
8
Considerable numbers of studies have been published
regarding prognostic factors for esophageal carcinoma.
However, only a few studies included in-depth analyses of
CRM involvement and homogeneous study groups. The
major advantage of our study is that we report CRM results
from a statistically comparable group of patients operated
on at a single center, with the same referral pattern,
selection process, classiﬁcation procedure, resection pro-
cedure, and follow-up protocol. Our data are not affected
by neoadjuvant chemoradiation or differences in surgical
procedure.
Extension of CRM is correlated with more advanced pT
status; perhaps other studies therefore lack consistent CRM
measurements. However, tumor depth (pT) is only related
to extent of tumor ingrowth in layers, whereas CRMs may
also depend on differences in cellular layer thickness of the
esophageal wall and the performed surgical technique of
resection. For example, unexpected ruptures or incomplete
resection may occur during surgery, particularly when
stretching or dissecting the esophagus from the perie-
sophageal tissue during transhiatal procedures (Fig. 3).
13
Therefore it is plausible that adequately performed exten-
ded transthoracic resection reduces the likelihood of
involvement of CRMs and this may partly explain the
improved survival in the randomized study of Hulscher
et al.
24 Moreover, it explains the independent prognostic
factor for development of recurrent disease and survival of
CRM involvement, independent of pT and pN classiﬁca-
tion. In advocating a surgical procedure, the ideal control
group to differentiate pattern of recurrence (local versus
recurrence outside the conduit) and survival would consist
of patients who underwent a non-en bloc procedure (i.e.,
transhiatal resection) with a positive circumferential mar-
gin. Hence, CRM measurements can serve as a useful
quality indicator of surgery.
As the proposed CRM [1 mm is not always feasible,
even with an en bloc transthoracic resection, neoadjuvant
chemoradiation can play an important role in increasing the
ratio of clear CRMs. In this study no patients underwent
study-related neoadjuvant treatment. Therefore no data on
the effect of neoadjuvant treatment on CRM involvement
can be given. However, recent studies showed that neo-
adjuvant multimodality treatment signiﬁcantly reduces
CRM involvement.
5,25,26 With the worse prognosis of
CRM involvement in mind, this could signify an important
beneﬁt of neoadjuvant treatment and might even explain in
part the improved results of this type of therapy. Since
most patients with esophageal cancer currently receive
induction therapies, CRM measurements could be used as a
marker of tumor regression after neoadjuvant treatment. In
rectal cancer, CRM measurements after neoadjuvant ther-
apy can predict local recurrence and a subsequently
worsened outcome.
10
Inrecentyearsmanystudieshavesuggestedanadaptation
of the TNM staging system with assimilation of many dif-
ferent, scientiﬁcally proven prognostic factors.
17,20,22,23,27
With increasing knowledge about the biological behavior
and ﬁndings of strong prognostic variables other than TNM,
adaptation of the staging procedure will be inevitable in the
near future. We suggest that CRM measurement should be a
partoftheclassiﬁcation,becauseitseemstohavemorevalue
than pT status alone. At least integration of CRM measure-
mentwiththeRclassiﬁcation ispivotal.Weproposethatthe
resection (R) classiﬁcation should not only include clear
longitudinal margins but also circumferential resection
margins with a critical limit of 1.0 mm.
In conclusion, we advocate integration of the circum-
ferential resection margin (CRM) with a limit of B1.0 mm
and[1.0 mm into the routine pathologic staging procedure
Circumferential Margins in Esophageal Cancer 819of esophageal carcinoma. CRM is an important underesti-
mated independent prognostic factor for development of
recurrent disease and survival. Therefore, patients with
unfavorable CRM involvement should be approached as
patients with an R1 resection with corresponding outcome.
Furthermore, we recommend radical transthoracic exten-
ded resection to achieve optimal surgical margins,
including ample circumferential resection margins, for
better locoregional control and long-term outcome.
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